Dr. Pierric MARCHAND – Founder & General Manager of Holodiag – and Pierfrancesco MOROSINI – President & CEO of Icrom, President of AschimFarma, and President of Holodiag – gave an interview highlighting the group’s strengths and differentiating factors in the highly competitive CDMO market.
In 2024, Icrom acquired Holodiag to expand its expertise in solid state, polymorphism, and crystallization process development for small molecules. This strategic move reinforces Icrom’s position as a trusted CDMO, combining solid-state excellence with GMP manufacturing of high-potent APIs.
